Pelvic Floor Stimulation as a Treatment of Urinary and Fecal Incontinence
Defines coverage stance for electrical or magnetic pelvic floor stimulation used to treat urinary or fecal incontinence for members covered by Premera Blue Cross.
Policy reinstated from Archive status and updated with literature review through July 7, 2025; effective for dates of service on or after September 4, 2026.
Electrical or magnetic stimulation of the pelvic floor muscles as a treatment for urinary or fecal incontinence is considered investigational.
Policy updated with multiple recent references and guideline citations through 2025/2026 (including AUA/SUFU, ASCRS, NICE, Cochrane reviews, and recent RCTs/systematic reviews).
Coverage Criteria — Pelvic Floor Stimulation
Urinary incontinence — Investigational
Coverage stance
Examples include Regenesis EMS Chair, Emsella, NeoControl and vaginal/rectal probes.
Fecal incontinence — Investigational
Coverage stance
Systematic reviews and RCTs have not demonstrated consistent benefit; limited sham-controlled trials.
Investigational / Not medically necessary
Policy stance as stated in this segment
Policy reinstated from Archive status and updated with literature review through July 7, 2025; effective for dates of service on or after September 4, 2026.
The policy identifies specific examples of devices used to deliver pelvic floor stimulation but clarifies the list is not exhaustive. Examples cited include the Regenesis EMS Chair, Emsella (formerly HPM-6000UF), NeoControl Pelvic Floor Therapy System, and various vaginal and rectal probes. These devices deliver electrical or magnetic pulses to the pelvic floor musculature and are referenced solely as examples of technologies evaluated under this policy.
This medical policy does not apply to Medicare Advantage members; refer to member benefit booklets or customer service for coverage determinations specific to individual plans.
Based on available evidence from systematic reviews and randomized trials, electrical or magnetic stimulation of the pelvic floor muscles for urinary or fecal incontinence is considered investigational. Systematic reviews and RCTs have not consistently demonstrated clinically meaningful improvements in symptoms, disease status, or quality of life compared with sham or other conservative treatments, and evidence for magnetic stimulation in fecal incontinence is lacking.
On reinstatement from archive, the policy restates the investigational classification: electrical or magnetic stimulation of the pelvic floor muscles as a treatment for urinary or fecal incontinence is considered investigational. The policy was updated with a literature review through July 7, 2025, and is effective for dates of service on or after September 4, 2026.
Coding
Provider Actions and Billing Guidance
Prior Authorization Required
Prior authorization is required for requests involving non-implantable pelvic floor stimulators. Providers should submit prior authorization when proposing use of non-implantable pelvic floor stimulators (for example, devices billed with HCPCS E0740 or CPT unlisted code 53899) so medical necessity can be reviewed given the policy position that pelvic floor stimulation for urinary or fecal incontinence is considered investigational.
Medicare National Coverage Requirements
Medicare National Coverage (NCD 230.8) requires a documented trial of pelvic muscle exercise (PME) training prior to coverage of non-implantable pelvic floor electrical stimulation for stress and/or urge urinary incontinence in cognitively intact patients. Although the NCD addresses urinary incontinence, it does not mention fecal incontinence. Providers should document PME trial results when seeking consideration under Medicare rules.
- Covered under Medicare only when there is a documented trial of PME training and the patient is cognitively intact
- NCD addresses stress and/or urge urinary incontinence; fecal incontinence is not specified
Step Therapy
Step therapy: No step therapy protocol beyond conservative management and PME trial (as noted by Medicare NCD) is specified in this policy. Providers should follow plan-specific benefit rules; if a payer requires additional stepwise treatments, that will be enforced through prior authorization review.
- No additional step therapy requirements described in this policy segment
- Document prior conservative treatments (e.g., PME training) in authorization requests
Investigational Therapy — Denial Risk
Denial risk: Electrical or magnetic stimulation of the pelvic floor muscles for treatment of urinary or fecal incontinence is considered investigational per this policy and may be denied. Providers submitting prior authorization requests should include clinical evidence supporting medical necessity; absence of such evidence may lead to denial.
- Therapy is considered investigational for both urinary and fecal incontinence
- Requests for coverage may be denied as not medically necessary
Background
Pelvic floor stimulation (PFS) refers to delivery of electrical or magnetic pulses to activate pelvic floor muscles and associated pudendal nerve pathways to improve urethral and anal sphincter function. Delivery methods vary and include intracavitary probes (vaginal or rectal), chair-based extracorporeal magnetic stimulation, and other external applicators; stimulus parameters, treatment setting, and schedules also differ across devices and studies.
Definitions
Revision History
Policy updated with literature review; no change in policy statement noted in history records.
Policy replaced/updated as recorded in history entries.
Related policies updated and an archived related policy (2.01.527) removed.
Related policies updated and an archived related policy (7.01.553) removed.
Policy archived; low review volume and low-cost procedure noted.
Policy reinstated from archive status (approved May 12, 2026) with 90-day provider notification; policy updated with literature review through July 7, 2025, and an investigational stance for electrical or magnetic pelvic floor stimulation reaffirmed; effective for dates of service on or after 2026-09-04.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.